IO-TKI Findings in nccRCC from KEYNOTE-B61
Following the 2024 ASCO Annual Meeting, Martin H. Voss, MD, discusses long-term follow-up data from the phase 2 KEYNOTE-B61 trial investigating pembrolizumab plus lenvatinib in the first-line treatment of advanced non–clear cell RCC.
Video content above is prompted by the following question(s):
- Please discuss long term follow-up data from the phase 2 KEYNOTE-B61 trial investigating pembrolizumab + lenvatinib in the first-line treatment of advanced non-clear cell renal cell carcinoma.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
McGregor and Participants Discuss Impact of Drug Efficacy and Histology on nccRCC Care
October 17th 2024During a Case-Based Roundtable® event, Bradley McGregor, MD, moderated a discussion on prognosis and treatment approaches for a patient with stage IV papillary renal cell carcinoma.
Read More
